Expert Insights: Novel Agents and Evolving Strategies in Myeloproliferative Neoplasms – A Focus on Myelofibrosis
Earn up to 0.5 CME/NCPD/CPE Credits/Contact Hours
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit™
- Nurses — maximum of 0.5 contact hours and 0.5 contact hour(s) in the area of pharmacology
- Pharmacists — 0.5 contact hours (.05 CEUs) of the Accreditation Council for Pharmacy Education
Watch the experts who are actively engaged in the care of patients with myelofibrosis as they reinforce key points and highlight the most clinically relevant data presented at the 2022 Society of Hematology Oncology Annual Meeting.
This activity is intended for community and academic medical oncologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with MF.
After participating in the activity, participants should be better able to:
- Develop strategies to personalize care based on risk stratification and symptom burden for patients with myeloproliferative neoplasms
- Review the most recent results from clinical trial investigating emerging treatment options and novel formulations in myelofibrosis
- Identify strategies to monitor and mitigate treatment-related toxicities in patients with myelofibrosis
Accreditation, Support and Credit Statements
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and Bio Ascend. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hours and 0.5 contact hour(s) in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hours (.05 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-22-113-H01-P
Type of Activity: Knowledge
Disclosure and Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Srdan Verstovsek, MD, PhD (Moderator)
United Energy Resources, Inc.
Professor of Medicine
Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Contracted Research: Incyte, Roche, Novartis, Gilead, Celgene, Bristol Myers Squibb, Sierra, PharmaEssentia, AstraZeneca, Protagonist
Consulting Fees: Bristol Myers Squibb, Novartis, Incyte, Sierra, CTI BioPharma, Constellation
Naveen Pemmaraju, MD
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Contracted Research: US Department of Defense, Affymetrix, SagerStrong Foundation, Karger Publishers
Consulting Fees: AbbVie, Aptitude Health, Astellas Pharma US, Inc., Blueprint Medicines, Bristol‐Myers Squibb, Celgene Corp, Cimeio Therapeutics AG, ClearView Healthcare Partners, CTI BioPharma, Dava Oncology, Immunogen, Incyte, Intellisphere, LLC., Novartis AG, Novartis Pharmaceuticals Corp, OncLive (Owned by Intellisphere, LLC), Patient Power, PharmaEssentia, Protagonist Therapeutics, Sanofi‐aventis, Stemline Therapeutics, Inc., Total CME, Cancer.Net, CareDx, EUSA Pharma, Inc., Pacylex, Aplastic Anemia & MDS International Foundation, Curio Science LLC, Dava Oncology, Imedex, Magdalen Medical Publishing, Medscape, Neopharm, PeerView Institute for Medical Education, Physicians Education Resource (PER), Postgraduate Institute for Medicine
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and Bio Ascend, the joint provider, do not have any relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in and receiving continuing education credit for this activity. During the accredited period, participants must: 1) read the educational objectives and conflict of interest disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation. A passing score of 70% or higher is needed to obtain credit.
Participants who complete the educational activity, pre- and post-test, and evaluation will receive an accredited continuing education credit certificate. You will receive your certificate from Bio Ascend.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board. If you have questions regarding your certificate, please contact Bio Ascend via email at email@example.com.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About this Activity
Medical Learning Institute, Inc. and Bio Ascend are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.Support Statement
This CE activity is supported through educational grants from from CTI Biopharma Corp.and Sierra Oncology, Inc.
Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.